Cg Oncology Inc (CGON) financials
Cg Oncology revenue and earnings by year
Cg Oncology's revenue was $4.04 million in the fiscal year to December 31, 2025, up 254.7% from the year before. Net income was -$161 million, -3985.0% of revenue. Since the fiscal year to December 31, 2021, revenue has shrunk 21.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 4 | 1 | 0 | 0 | 10 |
| Revenue growth | 254.7% | 458.3% | 6.8% | -98.2% | — |
| Operating income | -191 | -115 | -55 | -35 | -13 |
| Operating margin | -4722.1% | -10067.3% | -27180.9% | -18453.4% | -121.7% |
| Net income | -161 | -88 | -49 | -35 | -13 |
| Net margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% |
| Diluted EPS | -$2.08 | -$1.41 | -$15.65 | — | — |
| Free cash flow | -132 | -79 | -46 | -30 | -14 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CGON in Markets.
How Cg Oncology makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Commercial & Development Revenue | $1.15M | 99.1% |
| License & Collaboration Revenue | $10.0K | 0.9% |
See also: CGON returns
No forecast, no recommendation. This page describes Cg Oncology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.